Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFOXIRI + Cetuximab vs Bevacizumab in Right-sided Colon Cancer Liver Metastases
NCT04832776Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Apr 2021
- Primary completion
- Dec 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cetuximab in colon cancer, liver metastases, sponsored by Fudan University. Started Apr 2021; status: recruiting.
02
Drugs
cetuximab
03
Conditions
colon cancerliver metastases
Beyond the preview
Go deeper on NCT04832776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04832776.